Literature DB >> 10334913

Multidrug-resistant phenotype influences the differentiation of a human colon carcinoma cell line.

O Rimet1, A Mirrione, Y Barra.   

Abstract

The human colon carcinoma cell line HT29-D4, which constitutively expresses a very low level of the MDR1 gene product, was made multidrug resistant by transfection with a human MDR1 cDNA from the pHaMDR1/A expression vector and selection by colchicine. Resistant clones were 3- to 15-fold resistant to colchicine and were cross-resistant to doxorubicin (3- to 4-fold). MDR1 gene expression was associated with the expression of functional P-glycoprotein (gp-170); the function was reversed by verapamil and cyclosporin A. HT29-D4 cells are able to differentiate in vitro by replacement of glucose by galactose in the culture medium and also to release the carcinoembryonic antigen (CEA). Under these culture conditions, MDR1 mRNA and gp-170 were always expressed and the protein remained functional. Upon galactose treatment, resistant clones were less differentiated since they showed a heterogeneous monolayer organization accompanied by heterogeneous staining of cell-surface CEA and a high decrease (60-90%) of CEA release. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334913     DOI: 10.1006/bbrc.1999.0711

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Multidrug resistance increment in a human colon carcinoma cell line by colchicine.

Authors:  M J Ruiz Gómez; L Gil; A Souviron; M Martínez Morillo
Journal:  J Physiol Biochem       Date:  2000-03       Impact factor: 4.158

2.  ATP-binding Cassette Transporters Substantially Reduce Estimates of ALDH-positive Cancer Cells based on Aldefluor and AldeRed588 Assays.

Authors:  Jin Won Park; Kyung-Ho Jung; Youngjoo Byun; Jin Hee Lee; Seung Hwan Moon; Young Seok Cho; Kyung-Han Lee
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.